KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Operating Expenses: 2018-2025

Historic Operating Expenses for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to -$802.0 million.

  • BioNTech SE's Operating Expenses fell 6.96% to -$802.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 billion, marking a year-over-year increase of 1.61%. This contributed to the annual value of $3.0 billion for FY2024, which is 21.43% up from last year.
  • Latest data reveals that BioNTech SE reported Operating Expenses of -$802.0 million as of Q3 2025, which was down 13.03% from -$709.5 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Operating Expenses ranged from a high of -$299.7 million in Q2 2021 and a low of -$813.6 million during Q2 2024.
  • Over the past 3 years, BioNTech SE's median Operating Expenses value was -$709.5 million (recorded in 2025), while the average stood at -$695.9 million.
  • In the last 5 years, BioNTech SE's Operating Expenses plummeted by 131,817,022.98% in 2021 and then grew by 12.79% in 2025.
  • Quarterly analysis of 5 years shows BioNTech SE's Operating Expenses stood at -$460.3 million in 2021, then plummeted by 39.56% to -$642.4 million in 2022, then dropped by 17.58% to -$755.4 million in 2023, then declined by 2.22% to -$772.2 million in 2024, then decreased by 6.96% to -$802.0 million in 2025.
  • Its last three reported values are -$802.0 million in Q3 2025, -$709.5 million for Q2 2025, and -$665.3 million during Q1 2025.